登录 | 注册    关注公众号  
微信公众号
搜索
 > 【B7-2】

B7-2信息

英文名称:Cluster of differentiation 86
中文名称:分化群86
靶点别称:FUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Antigen,LAB72,B7-2,B7.2,B7-2 Antigen
上市药物数量:2
临床药物数量:1
最高研发阶段:批准上市

B7-2产品列表

 
评论(9)
CD6-H5223|Human B7-2 / CD86 Protein, His Tag (MALS verified)
  1. 131XXXXXXX6
  2. 0人赞
  3. 一个新的试验不得不需要尝试新的试剂,做抗体药少不了优质抗原的使用,之前用过你们的抗原,效果很好,这次买来该产品用于试验,效果一如既往的不错,后续继续支持。
  4. 2022-04-21
CD6-H5223|Human B7-2 / CD86 Protein, His Tag (MALS verified)
  1. 151XXXXXXX5
  2. 0人赞
  3. 经过实验室小伙伴的推荐,通过对后续实验结果的跟踪发现该产品在结果上有很强的对比力,为我后续的实验提供了很好的依据,推动了项目的进行!!
  4. 2022-04-21
CD6-H5223|Human B7-2 / CD86 Protein, His Tag (MALS verified)
  1. 138XXXXXXX8
  2. 0人赞
  3. 从多个抗体中最终筛选出了这个产品用于实验,结果比其它品牌的都要好,成为我们实验的首选,价格货期也都很合适,各方面都挺满意的。
  4. 2022-04-22
 

B7-2 分子别名

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

B7-2 分子背景

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 前沿进展

B7-2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg 批准上市 百时美施贵宝 Nulojix EU 肾脏移植排斥 Bristol-Myers Squibb Pharma Eeig 2011-06-15 肾脏移植排斥, 器官移植排斥 详情
Abatacept 阿巴西普 ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC 批准上市 百时美施贵宝 Orencia United States 移植物抗宿主病 Bristol Myers Squibb Srlcompany 2005-12-23 关节炎, I型黏多糖贮积症, 免疫紊乱, 局灶性节段性肾小球硬化症, 再生障碍性贫血, 银屑病, 系统性红斑狼疮, 银屑病关节炎, 溃疡性结肠炎, 哮喘, 荨麻疹, Sjogren-Larsson综合征, 肌病, 普通可变性免疫缺陷, 关节痛, 风湿性多肌痛, 肾病综合征, 白细胞粘附缺陷综合征, 葡萄膜炎, 眼部疾病, 慢性肉芽肿病, 噬血细胞性淋巴组织细胞增多症, 弥漫性硬皮病, 心肌炎, 克罗恩病, 白塞病综合征, Kostmann综合征, 白癜风, 镰状细胞血症, 血小板机能不全, Sjtoegren综合征, 复发性多软骨炎, 抗中性粒细胞胞浆抗体相关性血管炎, 重症肌无力, 韦格纳肉芽肿, 威斯科特-奥尔德里奇综合征, 免疫球蛋白G4相关疾病, 斑秃, 巨细胞性动脉炎, 肌炎, 皮肌炎, 类风湿关节炎, 移植物抗宿主病, 强直性脊柱炎, 新型冠状病毒肺炎, 多发性肌炎, Chediak-Higashi综合征, β-地中海贫血, 范科尼贫血, 结节病, 系统性硬皮病 详情

B7-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌 详情
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) 临床一期 北京伟德杰生物科技有限公司 类风湿关节炎 详情
ASP-2408 ASP-2408 Maxygen 详情
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 Kahr Medical 详情

消息提示

请输入您的联系方式,再点击提交!

确定